Relationship between cisplatin administration and the development of ototoxicity

Journal of Clinical Oncology

Volumn 24, Issue 6, 2006, Pages 918-924

  Rademaker Lakhai, Jeany M ^a   Crul, Mirjam ^a   Zuur, Lot ^a   Baas, Paul ^a   Beijnen, Jos H ^a   Simis, Yvonne J W ^a   Van Zandwijk, Nico ^a   Schellens, Jan H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; FOLLOW UP; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MAXIMUM ALLOWABLE CONCENTRATION; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AUDIOMETRY; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HEARING; LUNG TUMOR; MALE; MIDDLE AGED;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; AUDIOMETRY; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEARING; HEARING LOSS; HEARING LOSS, HIGH-FREQUENCY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 33644915563     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.077     Document Type: Article

References (21)

1. Kaufman Arenberg I: Dizziness and Balance Disorder: An Interdisciplinary Approval. New York, NY, Kugler, 1993
2. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77:1355-1362, 1998
3. De Jongh FE, van Veen RN, Veltman SJ, et al: Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88:1199-1206, 2003
4. Planting AS, de Mulder PH, de Graeff A, et al: Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer 33:61-65, 1997
5. Van der Hulst RJ, Dreschler WA, Urbanus NA: High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 97:133-137, 1988
6. Reddel RR, Kefford RF, Grant JM, et al: Ototoxicity in patients receiving cis-platinum: Importance of dose and method of drug administration. Cancer Treat Rep 66:19-23, 1982
7. Schaefer SD, Wright CG, Post JD, et al: Cisplatinum vestibular toxicity. Cancer 47:857-859, 1981
8. Strauss M, Towfighi J, Lipton A, et al: Cisplatinum ototoxicity: Clinical experience and temporal bone histopathology. Laryngoscope 93:1554-1559, 1983
9. Wake M, Takeno S, Ibrahim D, et al: Carboplatin ototoxicity: An animal model. J Laryngol Otol 107:585-589, 1993
10. Van Warmerdam LJ, Rodenhuis S, Van der Wall E, et al: Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 73:979-984, 1996
11. Crul M, Schoemaker NE, Pluim D, et al: Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 9:3526-3533, 2003
12. Rademaker-Lakhai JM, Crul M, Pluim D, et al: Phase I clinical and pharmacologic study of weekly versus twice-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anticancer Drugs 16:1029-1036, 2005
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment of cancer: National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, National Cancer Institute, Division of Cancer Treatment, 1988
15. Committee on Hearing and Equilibrium guidelines for the evaluation of results of treatment of conductive hearing loss: American Academy of Otolaryngology-Head and Neck Surgery Foundation Inc. Otolaryngol Head Neck Surg 113:186-187, 1995
16. Schaefer SD, Post JD, Close LG, et al: Ototoxicity of low- and moderate-dose cisplatin. Cancer 56:1934-1939, 1985
17. Montaguti M, Brandolini C, Ferri GG, et al: Cisplatin and carboplatin induced ototoxicity in children: Clinical aspects and perspectives for prevention. Acta Otorhinolaryngol 22:14-18, 2002
18. Andersson A, Fagerberg J, Lewensohn R, et al: Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci 85:824-827, 1996
19. Johnson NP, Hoeschele JD, Rahn RO: Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichloro-diammineplatinum (II) to DNA. Chem Biol Interact 30:151-169, 1980
20. McAlpine D, Johnstone BM: The ototoxic mechanisms of cisplatin. Hear Res 47:191-203, 1990
21. Huang MY, Schacht J: Drug-induced ototoxicity: Pathogenesis and prevention. Med Toxicol Adverse Drug Exp 4:452-467, 1989